bupropion SR for weight
Selected indexed studies
- The Black Book of Psychotropic Dosing and Monitoring. (Psychopharmacol Bull, 2024) [PMID:38993656]
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). (Obesity (Silver Spring), 2013) [PMID:23408728]
- Pharmacotherapy for Obesity: Recent Updates. (Clin Pharmacol, 2025) [PMID:40995421]
_Worker-drafted node — pending editorial review._
Connections
bupropion SR for weight is a side effect of
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). (2013) pubmed
- Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. (2010) pubmed
- Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. (2016) pubmed
- Obesity Pharmacotherapy. (2018) pubmed
- Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? (2011) pubmed
- Pharmacotherapy for Obesity: Recent Updates. (2025) pubmed
- Pharmacotherapy for Obesity. (2016) pubmed
- Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. (2002) pubmed
- Bupropion SR for the treatment of smokeless tobacco use. (2007) pubmed